Hydrocortisone — Drug Intelligence | 46 EU Trials

Filter these 46 trials by condition, phase, country and more.

Open in Search →

46 Registered trials

16 Recruiting

21 Completed trials

34 Sponsors

27 Countries

Phase III

Phase II

Phase IV

Phase III: 18 Phase II/III: 2 Phase II: 15 Phase I/II: 2 Phase III/IV: 1 Phase IV: 6 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

3 serious breaches 45 temporary halts 3 urgent safety measures 1 unexpected event 2 corrective measures across 7 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma recurrent 2 Polymyositis 2 Dermatomyositis 2 Idiopathic inflammatory myopathy 1 Rheumatoid arthritis 1 Anti-myelin-associated glycoprotein antibodies positive 1 Dermatitis atopic 1 Diffuse large B-cell lymphoma refractory 1 Pyoderma gangrenosum 1 Cardiac arrest 1 Prostate cancer metastatic 1 Binge eating 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 3 Allogene Therapeutics Inc. 2 Amsterdam UMC Stichting 2 Anaptysbio Inc. 2 Assistance Publique Hopitaux De Paris 2 Gcp-Service International West GmbH 2 Pfizer Inc. 2 Prinses Maxima Centrum voor Kinderoncologie B.V. 2 Spruce Biosciences Inc. 2 Tiohundra AB 2 Universitair Medisch Centrum Utrecht 2 AbbVie Deutschland GmbH & Co. KG 1

All trials

46 total

A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Not authorised

2022-500721-32-00 Phase II 2 countries Gcp-Service International West GmbH
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised

2023-503522-40-00 Phase II 2 countries Anaptysbio Inc.
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections (IMPACT) Not authorised

2025-522215-42-00 Phase IV 1 country Copenhagen University Hospital
Prolonged corticosteroid therapy in scheduled cardiac surgery in intermediate/high-risk patients: a prospective multicenter randomized contr… Pending

2024-517699-39-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending

2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending

2025-522019-40-00 Phase I/II 7 countries Novartis Pharma AG
SHIELD – Swift Hydrocortisone Intervention after trauma exposure Pending

2025-523350-13-02 Phase II 1 country Amsterdam UMC Stichting
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Phase III 10 countries Erasca Inc.
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting

2022-502739-20-00 Phase III 10 countries Pfizer Inc.
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Phase III 19 countries Princess Maxima Center For Pediatric Oncology
Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting

2024-518493-14-00 Phase II/III 1 country Les Hopitaux Universitaires De Strasbourg
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Phase III 15 countries Merck Sharp & Dohme LLC
Perioperative hydrocortisone treatment in pancreatoduodenectomy – randomised double-blinded placebo-controlled interventional trial (PD-HYDR… Recruiting

2024-517877-26-00 Phase II/III 1 country Universitaetsklinikum Schleswig-Holstein AöR
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortison… Recruiting

2024-519667-18-00 Phase IV 7 countries Amsterdam UMC Stichting
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Phase I/II 7 countries Merck Sharp & Dohme LLC
Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting

2023-505262-28-00 Phase I (Other) 5 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting

2024-514648-10-00 Phase III 6 countries Pfizer Inc.
Cortisol in personalized treatment for posttraumatic stress disorder (PTSD) Recruiting

2024-516427-13-00 Phase IV 1 country Stichting Radboud universitair medisch centrum
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Phase III 14 countries Merck Sharp & Dohme LLC
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Phase III 19 countries Argenx
The CORTAD study Recruiting

2024-512888-31-00 Phase III/IV 1 country Helse Bergen HF
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Phase III 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
A RANDOMIZED DOUBLE BLIND, PLACEBO-CONTROLLED NATIONAL MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY OF AZATHIOPRINE FOR THE PREVENTION… Recruiting

2022-500520-30-00 Phase III 1 country Hospices Civils De Lyon
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus

Showing 1–24 of 46 trials

← All drugs A–Z